

Figure 1




Figure 2




Fig. 3A

Patient ID	#PEPI / HPV-16 E6 Pools										#PEPI / HPV-16 E7 Pools														
	19-Jan	29-Nov	21-39	31-49	41-59	51-69	61-79	71-89	81-99	91-109	101-119	111-129	121-139	131-149	141-158	19-Jan	29-Nov	21-39	31-49	41-59	51-69	61-79	71-89	81-98	
1	TN	TN	TN	TN	TN	TN	TN	TN	TN	TN	FN	TN	TN	TN	TN	TN	FP	TN	TN	TN	TN	TN	TN	TN	TN
2	FN	FN	TN	TN	TN	FP	TN	TN	TN	TN	TN	TN	TN	TN	TN	FP	FP	TN	TN	FP	TN	TN	TN	TN	TN
3	TN	TN	TN	TN	TN	TP	TN	TN	TN	TN	TN	FN	TN	TN	TN	TN	TN	TN	TN	TN	TN	TN	TN	TN	TN
4	TN	FN	TN	TN	TN	FN	TN	TN	TN	TN	TN	TN	TN	TN	TN	TN	TN	TN	TN	TN	TN	TN	TN	TN	TN
6	TN	TN	TN	FN	TN	FP	TN	TN	TN	TN	FN	TN	TN	TN	TN	FP	TN	TN	TN	TN	TN	TN	TN	TN	FP
7	TN	TN	TN	TN	TN	FN	TN	TN	TN	TN	TN	TN	TN	TN	TN	TN	TN	TN	TN	TN	TN	TN	TN	TN	TN
8	TN	FN	TN	FN	TN	FN	TN	FP	TN	TN	FN	TN	TN	TN	FN	TN	TN	TN	TN	TP	TN	TN	TN	TN	TN
9	TN	TN	TN	TN	TN	FN	TN	FP	TN	TN	TN	TN	TN	TN	TN	TN	TN	TN	TN	FP	TN	TN	TN	TN	TN
10	TN	TN	TN	TN	TN	TP	TN	TN	TN	TN	TN	TN	TN	TN	TN	TN	TN	TN	TN	FP	TN	TN	TN	FP	TN
11	TN	FN	TN	TN	TN	TN	TN	TN	FP	TN	TN	TN	TN	TN	TN	TN	TN	TN	TN	TN	TN	TN	TN	TN	TN
13	TN	TN	TN	TN	TN	FN	TN	TN	TN	FN	TN	TN	TN	TN	TN	TN	TN	TN	TN	TN	TN	TN	TN	TN	TN
16	TN	TN	TN	TN	TN	TP	TN	TN	TN	FN	TN	TN	TN	TN	TN	TN	TN	TN	TN	TN	TN	TN	TN	TN	TN
18	TN	TN	TN	TN	TN	FP	TN	TN	TN	TN	NL	TN	TN	NL	TN	TN	TN	TN	TP	TN	TN	TN	TN	TN	TN
22	TN	FN	TN	TN	TN	TP	TN	TN	TN	TN	NL	TN	TN	NL	TN	FP	TN	TN	TN	FP	TN	TN	TN	TN	TN
23	TN	TN	TN	FN	TN	TN	TN	TN	TN	FN	TN	NL	TN	NL	FN	TN	TN	TN	TN	TN	TN	TN	TN	TN	TN
24	TN	TN	TN	TN	TN	TP	TN	TN	TN	FN	TN	TN	TN	TN	TN	FP	TN	TN	TN	TN	TN	TN	TN	FN	FP
27	TN	TN	TN	TN	TN	TN	TN	TN	TN	TN	TN	TN	TN	TN	TN	TN	TN	TN	TN	TN	TN	TN	TN	TN	TN
28	TN	TN	TN	TN	TN	FP	TN	TN	TN	TN	TN	TN	TN	TN	TN	TN	TN	TN	FP	TN	TN	TN	TN	TN	TN
29	FN	TN	FN	TN	TN	TN	TN	TN	TN	FN	TN	TN	TN	TN	TN	TN	TN	TN	TN	TN	TN	TN	TN	TN	TN
30	TN	TN	TN	TN	TN	FP	TN	TN	TN	TN	TN	TN	TN	TN	TN	TN	TN	TN	TN	TN	TN	TN	TN	TN	TN
100	TN	TN	TN	TN	TN	FN	TN	TN	TN	TN	NL	TN	TN	TN	TN	TN	TN	TN	TN	TN	TN	TN	TN	TN	TN
102	TN	TN	TN	TN	TN	TP	TN	TN	FP	TN	TN	NL	TN	TN	TN	TN	TN	TN	TN	TN	FN	TN	TN	NL	TN
103	TN	FN	FN	TN	TN	TN	TN	TN	TN	TN	TN	NL	TN	TN	TN	TN	TN	TN	TN	TN	TN	TN	TN	NL	TN
105	TN	TN	TN	TN	TN	TP	FN	TN	TN	TN	TN	TN	TN	TN	TN	FP	TN	TN	TN	FP	TN	TN	TN	NL	TN
107	TN	TN	TN	TN	TN	TN	TN	TN	TN	FN	TN	TN	TN	TN	TN	TN	TN	TN	TN	TN	TN	TN	TN	NL	TN

Patient ID	#epitope / HPV-16 E6 Pools										#epitope / HPV-16 E7 Pools														
	19-Jan	29-Nov	21-39	31-49	41-59	51-69	61-79	71-89	81-99	91-109	101-119	111-129	121-139	131-149	141-158	19-Jan	29-Nov	21-39	31-49	41-59	51-69	61-79	71-89	81-98	
1	TN	FP	FP	TP	FP	FP	FP	FP	FP	FP	TP	FP	TN	TN	FP	FP	FP	FP	TN	FP	FP	FP	FP	FP	FP
2	TP	TP	FP	FP	FP	FP	FP	FP	FP	FP	TN	TN	FP	FP	FP	FP	FP	FP	TN	FP	FP	FP	FP	FP	FP
3	FP	FP	TN	FP	FP	TP	TN	FP	FP	FP	FP	TP	TN	FP	FP	FP	FP	TN	TN	FP	TN	TN	FP	FP	FP
4	FP	TP	TN	FP	FP	TP	TN	FP	FP	FP	FP	FP	FP	FP	FP	FP	FP	TN	TN	FP	TN	FP	FP	FP	FP
6	FP	FP	FP	FN	FP	FP	FP	FP	FP	FP	FP	TN	TN	TN	TN	FP	FP	FP	FP	FP	TN	FP	FP	FP	FP
7	FP	FP	FP	FP	FP	TP	TN	FP	FP	FP	FP	FP	FP	FP	FP	FP	TN	TN	TN	FP	TN	TN	FP	FP	FP
8	FP	TP	TN	TP	FP	TP	FP	FP	FP	FP	TP	FP	FP	FP	TP	FP	FP	TN	TN	TP	TN	FP	FP	FP	FP
9	FP	FP	TN	FP	TP	TP	TN	FP	FP	FP	FP	FP	FP	FP	FP	FP	FP	TN	TN	FP	TN	FP	FP	FP	FP
10	FP	FP	TN	FP	FP	TP	FP	FP	FP	FP	FP	FP	TN	FP	FP	FP	FP	TN	TN	FP	TN	TN	FP	FP	FP
11	FP	TP	FP	FP	FP	FP	FP	TN	FP	FP	FP	FP	FP	FP	FP	FP	FP	TN	TN	FP	TN	TN	FP	FP	FP
13	FP	FP	FP	FP	FP	TP	FP	FP	FP	TP	FP	FP	TN	FP	FP	FP	FP	TN	TN	FP	FP	TN	FP	FP	FP
16	FP	FP	FP	FP	FP	TP	TN	FP	TN	TP	FP	TN	FP	FP	FP	FP	FP	FP	FP	FP	TN	FP	FP	FP	FP
18	FP	FP	FP	FP	FP	FP	FP	FP	FP	FP	FP	FP	TN	FP	FP	FP	FP	TN	TN	TP	FP	FP	FP	FP	FP
22	FP	TP	FP	FP	FP	TP	FP	FP	FP	FP	FP	FP	TN	FP	FP	FP	FP	TN	TN	FP	TN	FP	FP	FP	FP
23	TN	FP	FP	TP	FP	FP	FP	FP	FP	TP	FP	FP	TP	FP	FP	FP	FP	FP	FP	FP	FP	TN	FP	FP	FP
24	TN	FP	FP	FP	FP	TP	FP	TN	FP	TP	TN	TN	FP	FP	FP	FP	FP	FP	FP	FP	TN	FP	FP	FP	FP
27	FP	FP	FP	FP	FP	FP	FP	FP	FP	FP	FP	FP	TN	FP	FP	FP	FP	TN	TN	FP	TN	FP	FP	FP	FP
28	FP	FP	TN	TN	FP	FP	FP	FP	FP	FP	TN	FP	TN	FP	FP	FP	FP	TN	TN	FP	FP	TN	FP	FP	FP
29	TP	FP	TP	FP	FP	FP	FP	FP	FP	TP	FP	FP	FP	FP	FP	FP	FP	TN	FP	FP	FP	FP	FP	FP	FP
30	FP	FP	FP	FP	FP	FP	FP	FP	FP	FP	FP	TN	TN	TN	FP	FP	FP	TN	TN	FP	FP	FP	FP	FP	FP
100	FP	FP	FP	FP	FP	TP	FP	FP	FP	FP	TN	TN	FP	FP	FP	FP	FP	FP	FP	FP	FP	FP	FP	FP	TN
102	FP	FP	FP	FP	FP	TP	FP	FP	FP	FP	TN	FP	FP	FP	FP	FP	FP	TN	TN	FP	FP	TN	FP	FP	TN
103	FP	TP	FP	FP	FP	FP	FP	FP	FP	FP	FP	FP	TN	FP	FP	FP	FP	TN	TN	FP	FP	TN	FP	FP	FP
105	FP	FP	FP	FP	FP	TP	TP	FP	FP	FP	TN	FP	TN	FP	FP	FP	FP	TN	TN	FP	TN	FP	FP	FP	FP
107	FP	FP	FP	FP	FP	FP	FP	FP	FP	TP	TN	FP	FP	FP	FP	FP	FP	FP	FP	FP	TN	FP	FP	FP	FP

Fig. 3B

Fig. 4

A

Patient ID	#PEPI / HPV-16 E6 & E7 Pools					
	E6.1	E6.2	E6.3	E6.4	E7.1	E7.2
1	FP	TP	TP	FN	TN	FN
2	FP	TP	TP	TN	TN	TP
3	TP	TP	TP	TP	TN	TP
4	TP	TP	TP	TP	FN	FN
6	TP	TP	TP	FN	TP	TP
7	TP	TP	TP	TP	TN	TP
8	TP	TP	TP	FN	FP	TP
9	TP	TP	TP	FN	FP	TP
10	FP	TP	TP	FN	TN	TP
11	TP	TP	FN	FN	FP	TP
13	TP	TP	TP	FN	TN	FN
16	TP	TP	TP	FN	FP	TP
18	FP	TP	TP	FN	FN	TP
22	TP	TP	TP	FN	FN	FN
23	FP	TP	TP	FN	TN	TN
24	FP	TP	TP	FN	TN	TP
27	TP	TP	TP	FN	FN	FN
28	TP	TP	TP	FN	TN	TP
29	FP	TP	TP	FN	FP	TP
30	FP	FP	FP	TN	FN	TP
100	TP	TP	TP	FN	TN	TP
102	TP	TP	TP	FN	TP	TP
103	TP	TP	TP	FN	TN	TN
105	TP	TP	TP	TP	TN	TN
107	TP	TP	FN	FN	FP	TP

B

Patient ID	#epitope / HPV-16 E6 & E7 Pools					
	E6.1	E6.2	E6.3	E6.4	E7.1	E7.2
1	FP	TP	TP	TP	FP	TP
2	FP	TP	TP	FP	FP	TP
3	TP	TP	TP	TP	FP	TP
4	TP	TP	TP	TP	FN	TP
6	TP	TP	TP	TP	TP	TP
7	TP	TP	TP	TP	FP	TP
8	TP	TP	TP	FN	FP	TP
9	TP	TP	TP	FN	FP	TP
10	FP	TP	TP	TP	FP	TP
11	TP	TP	TP	TP	FP	TP
13	TP	TP	TP	TP	FP	TP
16	TP	TP	TP	FN	FP	TP
18	FP	TP	TP	FN	TP	TP
22	TP	TP	TP	TP	TP	TP
23	FP	TP	TP	TP	FP	FP
24	FP	TP	TP	TP	FP	TP
27	TP	TP	TP	TP	TP	TP
28	TP	TP	TP	TP	FP	TP
29	FP	TP	TP	TP	FP	TP
30	FP	FP	FP	FP	TP	TP
100	TP	TP	TP	TP	FP	TP
102	TP	TP	TP	TP	TP	TP
103	TP	TP	TP	TP	FP	FP
105	TP	TP	TP	TP	FP	FP
107	TP	TP	TP	TP	FP	TP

Fig. 5




Figure 6





Figure 7



SUBSTITUTE SHEET (RULE 26)




Figure 9




Figure 10




Figure 10




Figure 10




Figure 10




Figure 11




Figure 12




Figure 13

CRC_P3 peptide (30 aa)

EpCam (15 aa)


MAGE-A8 (15 aa)

YVDEKAPEFSMQGLK DEKVAELVRFLRKY

PolyPEP1018 vaccine antigens	Pre-clinical Immunogenicity		Clinical Immunogenicity
	Model population (n=433)	CRC cohort (n=37)	
TSP50	53%	62%	OBERTO-101 (n=10) 70%
EpCAM	69%	41%	90%
Survivin	36%	32%	70%
Cage	68%	81%	50%
SPAG9	28%	3%	40%
FBXO39	90%	100%	60%
MAGE-A8	18%	0%	60%
Any antigen	98%	100%	90%
Any 2 antigens	92%	92%	90%
Any 3 antigens	72%	65%	80%

**Lorincz et al. Journal of Clinical Oncology 37, 2019 (suppl; abstr e14298).*

Figure 14A



Note: In the CAIRO3 trial the PFS1 was m8.5 month (95% CI 6.5-10.3)*
*CAIRO3 trial: Simkens et al. The Lancet 2015

Figure 14B




Figure 14C




Figure 15




Figure 16





Figure 17







Fig. 18 (Cont.)



• **Enrolled:**

- 160 subjects
- 3 vaccine doses

• **Manufacturing (GMP)**

- Warehouse: cca 6 month, \$900,000
- Fill&Finish/QC release: 6-8 weeks, \$34,000/patient

Fig. 19




Figure 20




Figure 21

Predicted Immunogenicity, PEPI = 13 : 10 CI95% [9,13] (antigen specific T cell responses)

Detected Immunogenicity: 13 (20-mers) & 13 (9-mers) antigen specific T cell responses

Positive T cell responses: >5 fold above control or >3 fold above control and >50 spots





Figure 22






Fig. 24




Figure 25




Fig. 26




Figure 27




Figure 28

